{"schema_version":"1.0","type":"article","title":"Codex 變身 AI 科學家？OpenAI 真正搶的是整套生命科學工作流","url":"https://drugnews.com.tw/articles/2026-09-10-openai-rosalind-workbench.html","markdown_url":"https://drugnews.com.tw/articles/2026-09-10-openai-rosalind-workbench.md","lang":"zh-Hant","date":"2026-09-10","publish_at":"2026-09-10T08:00:00+08:00","updated_at":"2026-09-10","category":"商業分析系列","topic":"商業分析系列","tags":["OpenAI","Rosalind Workbench","GPT-Rosalind","生命科學","AI Agent"],"summary":"文獻在資料庫、定序檔在伺服器、蛋白質結構在另一套工具、分析程式留在某位研究員的電腦，最後的實驗紀錄又散落在不同表單。科學家花掉大量時間，不是在解生物學，而是在搬資料、補上下文、確認上一個人到底做了什麼。","key_points":[],"facts":[],"sections":[],"references":[],"images":[{"alt":"Codex 變身 AI 科學家？真正的產品是工作流","url":"https://drugnews.com.tw/assets/articles/openai-rosalind-workbench/01_%E5%B0%81%E9%9D%A2_Codex%E8%AE%8A%E8%BA%ABAI%E7%A7%91%E5%AD%B8%E5%AE%B6.png"},{"alt":"Rosalind 三層架構：模型、工作台、科學工具","url":"https://drugnews.com.tw/assets/articles/openai-rosalind-workbench/02_Rosalind%E4%B8%89%E5%B1%A4%E6%9E%B6%E6%A7%8B.png"},{"alt":"研究閉環：問題、證據、分析、實驗與回饋","url":"https://drugnews.com.tw/assets/articles/openai-rosalind-workbench/03_%E7%A0%94%E7%A9%B6%E9%96%89%E7%92%B0.png"},{"alt":"商業化四關：模型、工具、治理與可驗證成果","url":"https://drugnews.com.tw/assets/articles/openai-rosalind-workbench/04_%E5%95%86%E6%A5%AD%E5%8C%96%E5%9B%9B%E9%97%9C.png"}],"cover_image":"https://drugnews.com.tw/assets/articles/openai-rosalind-workbench/01_%E5%B0%81%E9%9D%A2_Codex%E8%AE%8A%E8%BA%ABAI%E7%A7%91%E5%AD%B8%E5%AE%B6.png","publisher":{"name":"Drugnews｜藥時事","url":"https://drugnews.com.tw/","profile":"https://drugnews.com.tw/brand-profile.json"},"citation":"Drugnews｜藥時事（2026-09-10）。Codex 變身 AI 科學家？OpenAI 真正搶的是整套生命科學工作流。https://drugnews.com.tw/articles/2026-09-10-openai-rosalind-workbench.html","disclaimer":"本文僅供產業研究與知識分享，不構成投資、醫療、募資或個股建議。","translations":{},"relationship":"independent_editorial","disclosure_url":"https://drugnews.com.tw/policy/"}